Anne A. Moore, MSN, RNC, FAANP
Professor of Nursing
Vanderbilt University School of Nursing
THIS PROGRAM WAS ORIGINALLY PRESENTED AS A LIVE GROUP LECTURE SERIES (GLS) BEGINNING APRIL 30, 2009. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE GLS, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Fibromyalgia, a poorly understood chronic pain disorder, is now believed to be the most common rheumatologic diagnosis after osteoarthritis. Characterized by widespread, generalized, muscular pain, this disorder is estimated to afflict 2% to 4% of the US population – affecting mostly women between the ages of 20 and 55. Diagnosing and managing this disorder is a complex process for both health care providers and patients because definitive, objective testing does not yet exist and treatment involves a highly individualized multimodal mix of nonpharmacologic and pharmacotherapeutic regimens.
Nurse practitioners (NPs), frequently the most visible clinicians on the front lines of addressing acute and chronic health care problems, act as pivotal advocates and educators for patients. Because fibromyalgia symptoms can resemble those of many other diseases, diagnosis and effective treatment often elude affected patients for years, making it critical that NPs are well informed about this disease. Thus, NPs practicing in a wide variety of settings should be familiar with ways to identify fibromyalgia and work with patients in learning to incorporate an effective multimodal treatment approach.
Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education Target Audience
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Explain how to improve the diagnosis of fibromyalgia patients presenting with nonspecific symptoms.
Develop ways to overcome the challenges associated with treating fibromyalgia and its comorbidities.
Explain the benefits of combining nonpharmacologic therapeutic modalities with pharmacotherapy selections to improve clinical response in patients with fibromyalgia.
Describe the efficacy and safety profiles of different pharmacologic agents that are used to treat fibromyalgia.
Ms. Moore discloses that she has been a consultant for Duramed Pharmaceuticals, Inc. and has been a member of the speakers’ bureaus for Proctor & Gamble Pharmaceuticals, Ther-Rx Corporation, and Wyeth Pharmaceuticals.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Credit Statements
This program is approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 0902057.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through an educational grant from Pfizer Inc.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, or Pfizer Inc.